Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus

Thrombosis and Haemostasis

Volumn 106, Issue 3, 2011, Pages 416-422

  Alessi, Marie Christine ^a,b   Nicaud, Viviane ^a   Scroyen, Ilse ^a,b   Lange, Celine ^c,d   Saut, Noemie ^a,b   Fumeron, Frederic ^a,e   Marre, Michel ^a,e   Lantieri, Olivier ^f   Fontaine Bisson, Benedicte ^a,g   Juhan Vague, Iréne ^a,b   Balkau, Beverley ^c,d   Tregouet, David Alexandre ^a   Morange, Pierre Emmanuel ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Regional Institute for Health   (France)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Diabetes; Metabolic syndrome; PAI 1; Vitronectin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK; TIME FACTORS; VITRONECTIN;

EID: 80052304526     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0179     Document Type: Article

References (36)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
2. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250
3. Hu G, Qiao Q, Tuomilehto J, et al.; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076
4. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 2008; 51: 926-940
5. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45
6. Mertens I, Verrijken A, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-1314
7. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006
8. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000
9. Cigolini M, Targher G, Bergamo Andreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374
10. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 2000; 283: 221-228
11. Gray RP, Panahloo A, Mohamed-Ali V, et al. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 1997; 130: 171-178
12. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207
13. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116: 984-992
14. Festa A, D'Agostino R Jr, Tracy RP, et al. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1predict the development of type II diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137
15. Festa A, Williams K, Tracy RP, et al. Progression of plasminogen activator inhibitor- 1 and fibrinogen levels in relation to incident type II diabetes. Circulation 2006; 113: 1753-1759
16. Meigs JB, O'donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006; 55: 530-537
17. Ma L-J, Mao S-L, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346
18. Liang X, Kanjanabuch T, Mao SL et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 2006; 290: E103-E113.
19. Schäfer K, Fujisawa K, Konstantinides S, et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842
20. Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999; 31: 539-44
21. Declerck PJ, De Mol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461
22. Lebrun P, Baron V, Hauck CR, et al. Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. J Biol Chem 2000; 275: 38371-38377
23. Dupont DM, Madsen JB, Kristensen T, et al. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-1361
24. López-Alemany R, Redondo JM, Nagamine Y, et al. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-821
25. Kaido T, Yebra M, Cirulli V, et al. Impact of defined matrix interactions on insulin production by cultured human beta-cells: effect on insulin content, secretion, and gene transcription. Diabetes 2006; 55: 2723-2729
26. Balkau B, Eschwege E, Tichet J, et al. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab 1997; 23: 428-434
27. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
28. Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007; 30: 1795-1801
29. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-1039
30. Ekmekci H, Sonmez H, Ekmekci OB, et al. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 2002; 14: 221-225
31. Derer W, Barnathan ES, Safak E, et al. Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting. Circ Cardiovasc Intervent 2009; 2: 14-19
32. Tollefsen DM, Weigel CJ, Kabeer MH. The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem 1990; 265: 9778-9781
33. Chain D, Korc-Grodzicki B, Kreizman T, et al. The phosphorylation of the twochain form of vitronectin by proteinkinase A is heparin dependent. FEBS Lett 1990; 269: 221-225
34. Chain D, Korc-Grodzicki B, Kreizman T, et al. Endogenous cleavage of the Arg- 379-Ala-380 bond in vitronectin results in adistinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase A. Biochem J 1991; 274: 387-394
35. Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989; 990: 101-108
36. Yoneda A, Ogawa H, Kojima K, et al. Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry 1998; 37: 6351-6360.